Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Clinical Trial

Brain cancer patients left ‘devastated’ as new drug is rejected for NHS use

Patients who have taken the drug in clinical trials report remarkable results, including their tumours shrinking

The Independent UK

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

Benzinga

Company backed by Sam Altman gets FDA approval to trial ‘legal ecstasy’

Clinical trials of ‘safer MDMA’ could lead to new way of treating mental health problems, biotech firm says

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

EXCLUSIVE: Envoy Medical Cuts Capital Needs After FDA Approval For Final Trial Stage Of Cochlear Implant Trial

Envoy Medical Inc. (NASDAQ:COCH) announced on Tuesday that it has received U.S. Food and Drug Administration (FDA) approval to expand its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data from the first 10 patients.

Benzinga

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS).

Benzinga

Some new drugs aren’t actually ‘new’ – pharmaceutical companies exploit patents and raise prices for patients, but data transparency can help protect innovation

Pharmaceutical innovation saves lives. But not every “new” drug is truly new.

The Conversation

Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) rose sharply in pre-market trading after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism on Sep. 22.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Benzinga

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions.

Benzinga

Jim Cramer Expects Palantir To Reach New All-Time High

Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.

Benzinga

Gum disease treatment slows the thickening of arteries, clinical trial shows

New trial results show that intense gum disease treatment reduces how much the carotid artery narrows in otherwise healthy individuals. This suggests oral health should be taken seriously as a contributing factor in cardiovascular disease.

LiveScience

BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know

BioXcel Therapeutics Inc. (NASDAQ:BTAI) experienced significant after-hours momentum, jumping 19.09% to $6.24 in the after-hours trading session on Tuesday, as investors got ready for the release of important clinical trial results.

Benzinga

Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress

Shares of Protagenic Therapeutics Inc (NASDAQ:PTIX) are trading sharply higher Thursday afternoon, soaring over 100% midday after the company announced a key clinical milestone.

Benzinga

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years on Thursday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

inkl

Inside the World of Modern Clinical Trials: How Innovation Is Transforming Drug Development

Clinical trials have long served as the critical link between scientific discovery and real-world medical treatments. But in recent years, the way these trials are designed, managed, and executed has undergone a major transformation

Euronews

French scientists say light stimulation shows promise in slowing Parkinson's disease

An early-stage clinical trial in France appeared to help restore some brain function for three Parkinson's patients.

Benzinga

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

On Wednesday, Incannex Healthcare Inc. (NASDAQ:IXHL) released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.

MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

Benzinga

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ:SRPT) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company’s experimental treatments.

Evening Standard

Plan to link rare cancer sufferers to suitable clinical trials clears Commons

Allison Gardner MP dedicated her support for the Rare Cancers Bill to her mother, who died of pancreatic cancer.

LiveScience

Metformin may prevent severe morning sickness

Taking the diabetes drug metformin before pregnancy may reduce the risk of debilitating morning sickness by 70%, early data hint. But a clinical trial is still needed to confirm this finding.

Benzinga

ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results

ProKidney Ord Shs Class A (NASDAQ:PROK) shares are trading sharply higher Wednesday morning, following a marked surge on Tuesday driven by positive clinical trial data for its chronic kidney disease (CKD) treatment.

Benzinga

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University College London

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.